{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:49:06Z","timestamp":1761094146989,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5-T32-CA009515-28\/29"],"award-info":[{"award-number":["5-T32-CA009515-28\/29"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.bbmt.2014.09.012","type":"journal-article","created":{"date-parts":[[2014,10,6]],"date-time":"2014-10-06T02:04:45Z","timestamp":1412561085000},"page":"184-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation"],"prefix":"10.1016","volume":"21","author":[{"given":"Daniel N.","family":"Egan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Beppu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.09.012_bib1","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.09.012_bib2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2014.09.012_bib3","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3324\/haematol.2010.034173","article-title":"Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis","volume":"96","author":"Soverini","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.09.012_bib4","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.09.012_bib5","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.09.012_bib6","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1182\/blood.V79.11.3067.3067","article-title":"Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"79","author":"Barrett","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.012_bib7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.bbmt.2009.03.013","article-title":"Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia","volume":"15","author":"Copelan","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.012_bib8","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"100","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.012_bib9","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.09.012_bib10","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1158\/1078-0432.CCR-03-0580","article-title":"Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease","volume":"10","author":"DeAngelo","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2014.09.012_bib11","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","article-title":"Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study","volume":"23","author":"Hess","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.09.012_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bmt.1705554","article-title":"Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis","volume":"39","author":"Palandri","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.012_bib13","article-title":"The role of dasatinib in patients with Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT)","volume":"108","author":"Atallah","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.bbmt.2014.09.012_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000228587","article-title":"Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia","volume":"122","author":"Klyuchnikov","year":"2009","journal-title":"Acta Haematol"},{"key":"10.1016\/j.bbmt.2014.09.012_bib15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbmt.2009.11.026","article-title":"Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Wright","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.012_bib16","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Olavarria","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.012_bib17","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.012_bib18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","article-title":"Early molecular response to posttransplantation imatinib determines outcome in MRD\u00a0+ Philadelphia-positive acute lymphoblastic leukemia (Ph\u00a0+ ALL)","volume":"106","author":"Wassmann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.012_bib19","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR\u2013ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.09.012_bib20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3324\/haematol.2011.040261","article-title":"Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia","volume":"96","author":"Ram","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.09.012_bib21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.bbmt.2004.09.004","article-title":"Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation","volume":"10","author":"Anderlini","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.012_bib22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000314538","article-title":"Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse","volume":"123","author":"Kang","year":"2010","journal-title":"Acta Haematol"},{"key":"10.1016\/j.bbmt.2014.09.012_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/bmt.2009.6","article-title":"Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation","volume":"44","author":"Merante","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.012_bib24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.leukres.2008.03.031","article-title":"Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib","volume":"33","author":"Tiribelli","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2014.09.012_bib25","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s12032-009-9347-0","article-title":"Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion","volume":"27","author":"Czyz","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.bbmt.2014.09.012_bib26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.bbmt.2011.12.587","article-title":"Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"18","author":"Caocci","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.012_bib27","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2006-10-054080","article-title":"Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation","volume":"110","author":"Tichelli","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.012_bib28","first-page":"659","article-title":"Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib","volume":"91","author":"Kang","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.09.012_bib29","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.09.012_bib30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.09.012_bib31","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2014.09.012_bib32","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.leu.2404400","article-title":"A\u00a0novel BCR-ABL splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib","volume":"20","author":"Gruber","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.09.012_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph\u00a0+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.012_bib34","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","article-title":"Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations","volume":"117","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.012_bib35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.23666","article-title":"Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors","volume":"113","author":"Jones","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2014.09.012_bib36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutation BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy","volume":"96","author":"Hanfstein","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.09.012_bib37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.012_bib38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutation in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.012_bib39","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114005679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114005679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:50:25Z","timestamp":1761058225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114005679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1083879114005679"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.09.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}